Silencing of R-Spondin1 increases radiosensitivity of glioma cells

12Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Although radiation therapy is the most effective postoperative adjuvant treatment, it does not substantially improve the long-term outcomes of glioma patients because of the characteristic radioresistance of glioma. We found that R-Spondin1 (Rspo1) expression was elevated in high-grade gliomas and was associated with worse overall survival and disease-free survival. Rspo1 expression was also associated with reduced survival rates in glioma patients after treatment with radiotherapy and temozolomide (RT-TMZ). Importantly, Rspo1 was dramatically upregulated after radiation treatment in patients with glioma. Rspo1 silencing by shRNA potentiated glioma cell death upon radiation treatment. In a xenograft nude mouse model, combining radiation and silencing of Rspo1 potentiated tumor growth inhibition. Thus, combining radiotherapy with silencing of Rspo1 is a potential therapeutic approach.

Author supplied keywords

Cite

CITATION STYLE

APA

Gu, X., Wang, X., Xiao, H., Ma, G., Cui, L., Li, Y., … Li, K. (2015). Silencing of R-Spondin1 increases radiosensitivity of glioma cells. Oncotarget, 6(12), 9756–9765. https://doi.org/10.18632/oncotarget.3395

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free